Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis
The aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Prespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb tria...
Saved in:
| Published in | Ophthalmology science (Online) Vol. 5; no. 4; p. 100759 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Inc
01.07.2025
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2666-9145 2666-9145 |
| DOI | 10.1016/j.xops.2025.100759 |
Cover
| Abstract | The aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV).
Prespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb trial.
Adults with treatment-naïve neovascular age-related macular degeneration.
Participants were randomized 1:1:1 to receive a total of 6 intravitreal injections of ranibizumab 0.5 mg given 4-weekly, in combination with either 0.5 mg sozinibercept, 2 mg sozinibercept, or sham injection (control). Active PCV was determined at baseline by masked readers at an independent imaging center based on multimodal imaging, including OCT (notched, sharply peaked, or multilobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border), fundus photography (subretinal orange nodules), and fluorescein angiography (typical primarily occult multifocal lesions).
The primary end point was mean change from baseline in best-corrected visual acuity (BCVA) through week 24. Secondary end points included categorical changes in BCVA from baseline, anatomical changes in lesion morphology, and safety.
Of 366 participants, PCV was identified in 66 (18%) using predefined criteria. Sozinibercept combination therapy produced a dose response, with a mean BCVA change from baseline to week 24 of +13.54 (2 mg, n = 22) and +10.87 (0.5 mg, n = 24) letters compared with +6.9 letters for ranibizumab (n = 20), respectively. The 2 mg sozinibercept combination group had a superior BCVA gain versus ranibizumab (+6.7 letter difference in least squares mean; P = 0.0253) with more participants gaining ≥10 letters (77.3 vs. 47.4%) and ≥15 letters (40.9 vs. 31.6%) and fewer losing ≥5 letters (4.5 vs. 15.8%). Anatomic responses were consistent with functional outcomes and at week 24, fewer participants in the 2 mg sozinibercept combination group had subretinal fluid (19%) or intraretinal cysts (9.1%) than with ranibizumab monotherapy (42.1% and 25%, respectively). The safety profile of sozinibercept combination therapy was similar to ranibizumab.
In this predefined phase IIb subgroup of patients with PCV, sozinibercept combination therapy through inhibition of VEGF-C/-D achieved improved visual and anatomic outcomes compared with ranibizumab monotherapy consistent with the overall population.
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. |
|---|---|
| AbstractList | The aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV).
Prespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb trial.
Adults with treatment-naïve neovascular age-related macular degeneration.
Participants were randomized 1:1:1 to receive a total of 6 intravitreal injections of ranibizumab 0.5 mg given 4-weekly, in combination with either 0.5 mg sozinibercept, 2 mg sozinibercept, or sham injection (control). Active PCV was determined at baseline by masked readers at an independent imaging center based on multimodal imaging, including OCT (notched, sharply peaked, or multilobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border), fundus photography (subretinal orange nodules), and fluorescein angiography (typical primarily occult multifocal lesions).
The primary end point was mean change from baseline in best-corrected visual acuity (BCVA) through week 24. Secondary end points included categorical changes in BCVA from baseline, anatomical changes in lesion morphology, and safety.
Of 366 participants, PCV was identified in 66 (18%) using predefined criteria. Sozinibercept combination therapy produced a dose response, with a mean BCVA change from baseline to week 24 of +13.54 (2 mg, n = 22) and +10.87 (0.5 mg, n = 24) letters compared with +6.9 letters for ranibizumab (n = 20), respectively. The 2 mg sozinibercept combination group had a superior BCVA gain versus ranibizumab (+6.7 letter difference in least squares mean; P = 0.0253) with more participants gaining ≥10 letters (77.3 vs. 47.4%) and ≥15 letters (40.9 vs. 31.6%) and fewer losing ≥5 letters (4.5 vs. 15.8%). Anatomic responses were consistent with functional outcomes and at week 24, fewer participants in the 2 mg sozinibercept combination group had subretinal fluid (19%) or intraretinal cysts (9.1%) than with ranibizumab monotherapy (42.1% and 25%, respectively). The safety profile of sozinibercept combination therapy was similar to ranibizumab.
In this predefined phase IIb subgroup of patients with PCV, sozinibercept combination therapy through inhibition of VEGF-C/-D achieved improved visual and anatomic outcomes compared with ranibizumab monotherapy consistent with the overall population.
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. The aim of this study was to assess the efficacy of sozinibercept, a novel "trap" inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV).PurposeThe aim of this study was to assess the efficacy of sozinibercept, a novel "trap" inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV).Prespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb trial.DesignPrespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb trial.Adults with treatment-naïve neovascular age-related macular degeneration.ParticipantsAdults with treatment-naïve neovascular age-related macular degeneration.Participants were randomized 1:1:1 to receive a total of 6 intravitreal injections of ranibizumab 0.5 mg given 4-weekly, in combination with either 0.5 mg sozinibercept, 2 mg sozinibercept, or sham injection (control). Active PCV was determined at baseline by masked readers at an independent imaging center based on multimodal imaging, including OCT (notched, sharply peaked, or multilobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border), fundus photography (subretinal orange nodules), and fluorescein angiography (typical primarily occult multifocal lesions).MethodsParticipants were randomized 1:1:1 to receive a total of 6 intravitreal injections of ranibizumab 0.5 mg given 4-weekly, in combination with either 0.5 mg sozinibercept, 2 mg sozinibercept, or sham injection (control). Active PCV was determined at baseline by masked readers at an independent imaging center based on multimodal imaging, including OCT (notched, sharply peaked, or multilobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border), fundus photography (subretinal orange nodules), and fluorescein angiography (typical primarily occult multifocal lesions).The primary end point was mean change from baseline in best-corrected visual acuity (BCVA) through week 24. Secondary end points included categorical changes in BCVA from baseline, anatomical changes in lesion morphology, and safety.Main Outcome MeasuresThe primary end point was mean change from baseline in best-corrected visual acuity (BCVA) through week 24. Secondary end points included categorical changes in BCVA from baseline, anatomical changes in lesion morphology, and safety.Of 366 participants, PCV was identified in 66 (18%) using predefined criteria. Sozinibercept combination therapy produced a dose response, with a mean BCVA change from baseline to week 24 of +13.54 (2 mg, n = 22) and +10.87 (0.5 mg, n = 24) letters compared with +6.9 letters for ranibizumab (n = 20), respectively. The 2 mg sozinibercept combination group had a superior BCVA gain versus ranibizumab (+6.7 letter difference in least squares mean; P = 0.0253) with more participants gaining ≥10 letters (77.3 vs. 47.4%) and ≥15 letters (40.9 vs. 31.6%) and fewer losing ≥5 letters (4.5 vs. 15.8%). Anatomic responses were consistent with functional outcomes and at week 24, fewer participants in the 2 mg sozinibercept combination group had subretinal fluid (19%) or intraretinal cysts (9.1%) than with ranibizumab monotherapy (42.1% and 25%, respectively). The safety profile of sozinibercept combination therapy was similar to ranibizumab.ResultsOf 366 participants, PCV was identified in 66 (18%) using predefined criteria. Sozinibercept combination therapy produced a dose response, with a mean BCVA change from baseline to week 24 of +13.54 (2 mg, n = 22) and +10.87 (0.5 mg, n = 24) letters compared with +6.9 letters for ranibizumab (n = 20), respectively. The 2 mg sozinibercept combination group had a superior BCVA gain versus ranibizumab (+6.7 letter difference in least squares mean; P = 0.0253) with more participants gaining ≥10 letters (77.3 vs. 47.4%) and ≥15 letters (40.9 vs. 31.6%) and fewer losing ≥5 letters (4.5 vs. 15.8%). Anatomic responses were consistent with functional outcomes and at week 24, fewer participants in the 2 mg sozinibercept combination group had subretinal fluid (19%) or intraretinal cysts (9.1%) than with ranibizumab monotherapy (42.1% and 25%, respectively). The safety profile of sozinibercept combination therapy was similar to ranibizumab.In this predefined phase IIb subgroup of patients with PCV, sozinibercept combination therapy through inhibition of VEGF-C/-D achieved improved visual and anatomic outcomes compared with ranibizumab monotherapy consistent with the overall population.ConclusionsIn this predefined phase IIb subgroup of patients with PCV, sozinibercept combination therapy through inhibition of VEGF-C/-D achieved improved visual and anatomic outcomes compared with ranibizumab monotherapy consistent with the overall population.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.Financial DisclosuresProprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. The aim of this study was to assess the efficacy of sozinibercept, a novel "trap" inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Prespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb trial. Adults with treatment-naïve neovascular age-related macular degeneration. Participants were randomized 1:1:1 to receive a total of 6 intravitreal injections of ranibizumab 0.5 mg given 4-weekly, in combination with either 0.5 mg sozinibercept, 2 mg sozinibercept, or sham injection (control). Active PCV was determined at baseline by masked readers at an independent imaging center based on multimodal imaging, including OCT (notched, sharply peaked, or multilobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border), fundus photography (subretinal orange nodules), and fluorescein angiography (typical primarily occult multifocal lesions). The primary end point was mean change from baseline in best-corrected visual acuity (BCVA) through week 24. Secondary end points included categorical changes in BCVA from baseline, anatomical changes in lesion morphology, and safety. Of 366 participants, PCV was identified in 66 (18%) using predefined criteria. Sozinibercept combination therapy produced a dose response, with a mean BCVA change from baseline to week 24 of +13.54 (2 mg, n = 22) and +10.87 (0.5 mg, n = 24) letters compared with +6.9 letters for ranibizumab (n = 20), respectively. The 2 mg sozinibercept combination group had a superior BCVA gain versus ranibizumab (+6.7 letter difference in least squares mean; = 0.0253) with more participants gaining ≥10 letters (77.3 vs. 47.4%) and ≥15 letters (40.9 vs. 31.6%) and fewer losing ≥5 letters (4.5 vs. 15.8%). Anatomic responses were consistent with functional outcomes and at week 24, fewer participants in the 2 mg sozinibercept combination group had subretinal fluid (19%) or intraretinal cysts (9.1%) than with ranibizumab monotherapy (42.1% and 25%, respectively). The safety profile of sozinibercept combination therapy was similar to ranibizumab. In this predefined phase IIb subgroup of patients with PCV, sozinibercept combination therapy through inhibition of VEGF-C/-D achieved improved visual and anatomic outcomes compared with ranibizumab monotherapy consistent with the overall population. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. PurposeThe aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV). DesignPrespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb trial. ParticipantsAdults with treatment-naïve neovascular age-related macular degeneration. MethodsParticipants were randomized 1:1:1 to receive a total of 6 intravitreal injections of ranibizumab 0.5 mg given 4-weekly, in combination with either 0.5 mg sozinibercept, 2 mg sozinibercept, or sham injection (control). Active PCV was determined at baseline by masked readers at an independent imaging center based on multimodal imaging, including OCT (notched, sharply peaked, or multilobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border), fundus photography (subretinal orange nodules), and fluorescein angiography (typical primarily occult multifocal lesions). Main Outcome MeasuresThe primary end point was mean change from baseline in best-corrected visual acuity (BCVA) through week 24. Secondary end points included categorical changes in BCVA from baseline, anatomical changes in lesion morphology, and safety. ResultsOf 366 participants, PCV was identified in 66 (18%) using predefined criteria. Sozinibercept combination therapy produced a dose response, with a mean BCVA change from baseline to week 24 of +13.54 (2 mg, n = 22) and +10.87 (0.5 mg, n = 24) letters compared with +6.9 letters for ranibizumab (n = 20), respectively. The 2 mg sozinibercept combination group had a superior BCVA gain versus ranibizumab (+6.7 letter difference in least squares mean; P = 0.0253) with more participants gaining ≥10 letters (77.3 vs. 47.4%) and ≥15 letters (40.9 vs. 31.6%) and fewer losing ≥5 letters (4.5 vs. 15.8%). Anatomic responses were consistent with functional outcomes and at week 24, fewer participants in the 2 mg sozinibercept combination group had subretinal fluid (19%) or intraretinal cysts (9.1%) than with ranibizumab monotherapy (42.1% and 25%, respectively). The safety profile of sozinibercept combination therapy was similar to ranibizumab. ConclusionsIn this predefined phase IIb subgroup of patients with PCV, sozinibercept combination therapy through inhibition of VEGF-C/-D achieved improved visual and anatomic outcomes compared with ranibizumab monotherapy consistent with the overall population. Financial Disclosure(s)Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. Purpose: The aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Design: Prespecified subgroup analysis of a randomized, double-masked, sham-controlled phase IIb trial. Participants: Adults with treatment-naïve neovascular age-related macular degeneration. Methods: Participants were randomized 1:1:1 to receive a total of 6 intravitreal injections of ranibizumab 0.5 mg given 4-weekly, in combination with either 0.5 mg sozinibercept, 2 mg sozinibercept, or sham injection (control). Active PCV was determined at baseline by masked readers at an independent imaging center based on multimodal imaging, including OCT (notched, sharply peaked, or multilobular pigment epithelial detachments with or without a ring of hyperreflectivity along the inner border), fundus photography (subretinal orange nodules), and fluorescein angiography (typical primarily occult multifocal lesions). Main Outcome Measures: The primary end point was mean change from baseline in best-corrected visual acuity (BCVA) through week 24. Secondary end points included categorical changes in BCVA from baseline, anatomical changes in lesion morphology, and safety. Results: Of 366 participants, PCV was identified in 66 (18%) using predefined criteria. Sozinibercept combination therapy produced a dose response, with a mean BCVA change from baseline to week 24 of +13.54 (2 mg, n = 22) and +10.87 (0.5 mg, n = 24) letters compared with +6.9 letters for ranibizumab (n = 20), respectively. The 2 mg sozinibercept combination group had a superior BCVA gain versus ranibizumab (+6.7 letter difference in least squares mean; P = 0.0253) with more participants gaining ≥10 letters (77.3 vs. 47.4%) and ≥15 letters (40.9 vs. 31.6%) and fewer losing ≥5 letters (4.5 vs. 15.8%). Anatomic responses were consistent with functional outcomes and at week 24, fewer participants in the 2 mg sozinibercept combination group had subretinal fluid (19%) or intraretinal cysts (9.1%) than with ranibizumab monotherapy (42.1% and 25%, respectively). The safety profile of sozinibercept combination therapy was similar to ranibizumab. Conclusions: In this predefined phase IIb subgroup of patients with PCV, sozinibercept combination therapy through inhibition of VEGF-C/-D achieved improved visual and anatomic outcomes compared with ranibizumab monotherapy consistent with the overall population. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. |
| ArticleNumber | 100759 |
| Author | Baldwin, Megan E. Wykoff, Charles C. Khanani, Arshad M. Leitch, Ian M. Slakter, Jason Cheung, Chui Ming Gemmy Jackson, Timothy L. |
| Author_xml | – sequence: 1 givenname: Chui Ming Gemmy orcidid: 0000-0003-3358-3516 surname: Cheung fullname: Cheung, Chui Ming Gemmy email: gemmy.cheung.c.m@singhealth.com.sg organization: Medical Retina Department, Singapore National Eye Center, Singapore Eye Research Institute, Singapore, Singapore – sequence: 2 givenname: Timothy L. surname: Jackson fullname: Jackson, Timothy L. organization: Faculty of Life Sciences and Medicine, Kings College London, London, United Kingdom – sequence: 3 givenname: Charles C. surname: Wykoff fullname: Wykoff, Charles C. organization: Retina Consultants of Texas, Retina Consultants of America, Houston, Texas – sequence: 4 givenname: Arshad M. surname: Khanani fullname: Khanani, Arshad M. organization: Sierra Eye Associates, Reno, Nevada – sequence: 5 givenname: Ian M. surname: Leitch fullname: Leitch, Ian M. organization: Opthea Limited, Melbourne, Victoria, Australia – sequence: 6 givenname: Megan E. surname: Baldwin fullname: Baldwin, Megan E. organization: Opthea Limited, Melbourne, Victoria, Australia – sequence: 7 givenname: Jason surname: Slakter fullname: Slakter, Jason organization: Ophthalmology, NYU Langone Health, New York, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40933661$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1v1DAQjFAR_aB_gAfkx_KQq-3EyblClU6hLSdV4sRBXy3H2fQckjjYCSX9AfxunKZUCAl4sVermVntzhwGe61pIQheEbwgmCSn1eK76dyCYsp8A6eMPwsOaJIkIScx2_ut3g-Onasw9kgS0Zi8CPZjzKMoSchB8GNr7nWrc7AKuh6drNpehzcXV5dhdhq-e4My0-S6hQLd6X6HPkoP1fdDI3NUGos2ph47owtZo2xn7FzdSKeG2nSy341naLOTDtB6naONhQLKB7HtkN9aM3Ro1cp6dNq9DJ6XsnZw_PgfBZ8vLz5l78PrD1frbHUdKkZZHyaUcalKKBmP_BMxlgL3ojljJVaJBJkUcZpQitUylikQySnmDOKUx4wzFh0F61m3MLISndWNtKMwUouHhrG3QtpeqxoE5YSrCJY4VlEMGCTNlco5KXNFVAHgtU5mrc6arwO4XjTaKahr2YIZnPC35ss4pTz10NeP0CFvoHga_MsHD6AzQFnjnIXyCUKwmPwWlZj8FpPfYvbbk97OJPAX-6bBCqc0tAoKbUH1fiX9b_r5H3RV-ygoWX-BEVxlBuvdcYIIRwUW2ylQU54o81liKfYCZ38X-N_0n0Gg24I |
| Cites_doi | 10.1097/IAE.0b013e31824f91e8 10.1001/jamaophthalmol.2018.1804 10.1186/s12886-019-1278-8 10.1097/01.iae.0000249386.63482.05 10.1371/journal.pone.0077117 10.1016/j.ophtha.2023.02.001 10.1016/j.canlet.2013.12.004 10.1016/j.oret.2017.04.004 10.1016/j.oret.2019.10.008 10.1016/j.preteyeres.2016.04.002 10.1111/aos.12653 10.1016/j.ophtha.2020.08.006 10.2147/OPTH.S125676 10.1016/j.ajo.2014.05.004 10.1038/nrm2183 10.1016/j.apjo.2025.100144 10.1097/IAE.0b013e31823beb14 10.1038/s41598-023-35759-4 10.1016/j.cardiores.2004.12.002 10.1097/00006982-199010010-00001 10.1161/01.RES.0000118600.91698.BB 10.1007/s11060-010-0480-6 10.1016/j.preteyeres.2009.10.001 10.1016/j.exer.2015.12.014 10.1016/S0140-6736(24)00063-1 10.1167/iovs.12-9619 10.1186/s40942-017-0084-9 10.1074/jbc.273.12.6599 10.1016/S0140-6736(22)00010-1 10.1001/jamaophthalmol.2019.0565 10.1097/00006982-199515020-00003 10.1016/j.ophtha.2017.11.019 10.1097/IAE.0000000000001758 10.1016/j.ajo.2014.01.019 10.2147/OPTH.S385827 10.1016/j.exer.2006.05.007 10.1038/eye.2011.324 |
| ContentType | Journal Article |
| Copyright | 2025 American Academy of Ophthalmology American Academy of Ophthalmology 2025 by the American Academy of Ophthalmologyé. |
| Copyright_xml | – notice: 2025 American Academy of Ophthalmology – notice: American Academy of Ophthalmology – notice: 2025 by the American Academy of Ophthalmologyé. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 DOA |
| DOI | 10.1016/j.xops.2025.100759 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-9145 |
| EndPage | 100759 |
| ExternalDocumentID | oai_doaj_org_article_2919c3e804c34e0ea2bccb91fbc1cdee 40933661 10_1016_j_xops_2025_100759 S2666914525000570 1_s2_0_S2666914525000570 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Opthea Limited (Melbourne, Australia) |
| GroupedDBID | .1- .FO 0R~ AAEDW AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M~E OK1 ROL RPM Z5R 6I. AAFTH AAYXX CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c525t-6259acfef593ef53557e9defb55f0c6aea6d476220c84a7e1a92095e479459553 |
| IEDL.DBID | DOA |
| ISSN | 2666-9145 |
| IngestDate | Wed Aug 27 01:31:15 EDT 2025 Fri Sep 12 17:03:12 EDT 2025 Wed Sep 17 01:56:34 EDT 2025 Thu Aug 14 00:03:17 EDT 2025 Sat Sep 06 17:18:27 EDT 2025 Fri Aug 22 09:50:46 EDT 2025 Tue Aug 26 16:33:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Polypoidal choroidal vasculopathy PDT PCV IVT PLANET CNV ICG DARC SD-OCT TEAE BCVA Neovascular age-related macular degeneration VEGF-C/-D EVEREST II nAMD Sozinibercept photodynamic therapy Digital Angiography Reading Center treatment emergent adverse event choroidal neovascularization spectral-domain OCT indocyanine green Efficacy and safety of verteportin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy best-corrected visual acuity intravitreal |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2025 by the American Academy of Ophthalmologyé. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c525t-6259acfef593ef53557e9defb55f0c6aea6d476220c84a7e1a92095e479459553 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-3358-3516 |
| OpenAccessLink | https://doaj.org/article/2919c3e804c34e0ea2bccb91fbc1cdee |
| PMID | 40933661 |
| PQID | 3249847297 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2919c3e804c34e0ea2bccb91fbc1cdee proquest_miscellaneous_3249847297 pubmed_primary_40933661 crossref_primary_10_1016_j_xops_2025_100759 elsevier_sciencedirect_doi_10_1016_j_xops_2025_100759 elsevier_clinicalkeyesjournals_1_s2_0_S2666914525000570 elsevier_clinicalkey_doi_10_1016_j_xops_2025_100759 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-07-01 |
| PublicationDateYYYYMMDD | 2025-07-01 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Ophthalmology science (Online) |
| PublicationTitleAlternate | Ophthalmol Sci |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Spaide, Yannuzzi, Slakter (bib2) 1995; 15 Heier, Khanani, Ruiz (bib37) 2022; 399 bib36 Cao, Eriksson, Kubo (bib18) 2004; 94 Wong, Yanagi, Lee (bib5) 2016; 53 bib35 Ruamviboonsuk, Ng, Chaikitmongkol (bib40) 2025; 14 Tammela, Enholm, Alitalo, Paavonen (bib17) 2005; 65 Chaikitmongkol, Kong, Khunsongkiet (bib39) 2019; 137 Sen, Manayath, Shroff (bib9) 2023; 17 Sato, Kishi, Watanabe (bib7) 2007; 27 Joukov, Kumar, Sorsa (bib20) 1998; 273 Zhou, Zhao, Yuan, Chen (bib27) 2020; 20 Jackson, Slakter, Buyse (bib29) 2023; 130 Yanagi, Ting, Ng (bib33) 2018; 38 Ikeda, Yonemitsu, Onimaru (bib16) 2006; 83 Lanzetta, Korobelnik, Heier (bib38) 2024; 403 Khan, Engelbert, Imamura, Freund (bib6) 2012; 32 Lieu, Tran, Jiang (bib22) 2013; 8 Dugel, Boyer, Antoszyk (bib28) 2020; 4 Cheung, Lai, Ruamviboonsuk (bib4) 2018; 125 Lee, Lida, Ogura (bib13) 2018; 136 Adams, Alitalo (bib19) 2007; 8 Cabral, Mello, Lima (bib26) 2017; 3 Shin, Kwon, Byeon (bib31) 2015; 93 Spooner, Hon, Wijeyakumar, Chang (bib34) 2017; 11 Cheung, Lai, Teo (bib10) 2021; 128 Mukai, Kataoka, Tanaka (bib14) 2023; 13 Cabral, Lima, Mello (bib24) 2018; 2 Coscas, Yamashiro, Coscas (bib8) 2014; 158 Koh, Lee, Chen (bib11) 2012; 32 Yannuzzi, Sorenson, Spaide, Lipson (bib1) 1990; 10 Cho, Kim, Lee (bib12) 2012; 26 Grau, Thorsteinsdottir, von Baumgarten (bib23) 2011; 104 Puddu, Sanguineti, Traverso (bib25) 2016; 146 Jirarattanasopa, Ooto, Nakata (bib30) 2012; 53 Laude, Cackett, Vithana (bib3) 2010; 29 Li, Xie, Ding (bib21) 2014; 346 Kang, Kwon, Yi (bib32) 2014; 157 Ikeda (10.1016/j.xops.2025.100759_bib16) 2006; 83 Tammela (10.1016/j.xops.2025.100759_bib17) 2005; 65 Lanzetta (10.1016/j.xops.2025.100759_bib38) 2024; 403 Sato (10.1016/j.xops.2025.100759_bib7) 2007; 27 Cabral (10.1016/j.xops.2025.100759_bib26) 2017; 3 Cao (10.1016/j.xops.2025.100759_bib18) 2004; 94 Lee (10.1016/j.xops.2025.100759_bib13) 2018; 136 Wong (10.1016/j.xops.2025.100759_bib5) 2016; 53 Puddu (10.1016/j.xops.2025.100759_bib25) 2016; 146 Mukai (10.1016/j.xops.2025.100759_bib14) 2023; 13 Li (10.1016/j.xops.2025.100759_bib21) 2014; 346 Grau (10.1016/j.xops.2025.100759_bib23) 2011; 104 Ruamviboonsuk (10.1016/j.xops.2025.100759_bib40) 2025; 14 Kang (10.1016/j.xops.2025.100759_bib32) 2014; 157 Joukov (10.1016/j.xops.2025.100759_bib20) 1998; 273 Cabral (10.1016/j.xops.2025.100759_bib24) 2018; 2 Heier (10.1016/j.xops.2025.100759_bib37) 2022; 399 Laude (10.1016/j.xops.2025.100759_bib3) 2010; 29 Jirarattanasopa (10.1016/j.xops.2025.100759_bib30) 2012; 53 Spaide (10.1016/j.xops.2025.100759_bib2) 1995; 15 Yanagi (10.1016/j.xops.2025.100759_bib33) 2018; 38 Dugel (10.1016/j.xops.2025.100759_bib28) 2020; 4 Zhou (10.1016/j.xops.2025.100759_bib27) 2020; 20 Cheung (10.1016/j.xops.2025.100759_bib4) 2018; 125 Sen (10.1016/j.xops.2025.100759_bib9) 2023; 17 Shin (10.1016/j.xops.2025.100759_bib31) 2015; 93 Coscas (10.1016/j.xops.2025.100759_bib8) 2014; 158 Cheung (10.1016/j.xops.2025.100759_bib10) 2021; 128 Jackson (10.1016/j.xops.2025.100759_bib29) 2023; 130 Khan (10.1016/j.xops.2025.100759_bib6) 2012; 32 Lieu (10.1016/j.xops.2025.100759_bib22) 2013; 8 Yannuzzi (10.1016/j.xops.2025.100759_bib1) 1990; 10 Chaikitmongkol (10.1016/j.xops.2025.100759_bib39) 2019; 137 Adams (10.1016/j.xops.2025.100759_bib19) 2007; 8 Koh (10.1016/j.xops.2025.100759_bib11) 2012; 32 Cho (10.1016/j.xops.2025.100759_bib12) 2012; 26 Spooner (10.1016/j.xops.2025.100759_bib34) 2017; 11 |
| References_xml | – ident: bib36 article-title: OPT-302 with aflibercept in neovascular age-related macular degeneration (nAMD) (COAST). ClinicalTrials.gov Identifier NCT04757636 – volume: 3 start-page: 31 year: 2017 ident: bib26 article-title: Retinal and choroidal angiogenesis: a review of new targets publication-title: Int J Retina Vitreous – volume: 136 start-page: 786 year: 2018 end-page: 793 ident: bib13 article-title: Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial publication-title: JAMA Ophthalmol – volume: 53 start-page: 3663 year: 2012 end-page: 3672 ident: bib30 article-title: Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy publication-title: Invest Ophthalmol Vis Sci – volume: 83 start-page: 1031 year: 2006 end-page: 1040 ident: bib16 article-title: The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium publication-title: Exp Eye Res – volume: 26 start-page: 426 year: 2012 end-page: 433 ident: bib12 article-title: Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy publication-title: Eye (Lond) – volume: 273 start-page: 6599 year: 1998 end-page: 6602 ident: bib20 article-title: A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities publication-title: J Biol Chem – volume: 8 start-page: 464 year: 2007 end-page: 478 ident: bib19 article-title: Molecular regulation of angiogenesis and lymphangiogenesis publication-title: Nat Rev Mol Cell Biol – volume: 137 start-page: 661 year: 2019 end-page: 667 ident: bib39 article-title: Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy publication-title: JAMA Ophthalmol – volume: 14 year: 2025 ident: bib40 article-title: Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS) publication-title: Asia Pac J Ophthalmol (Phila) – volume: 32 start-page: 1057 year: 2012 end-page: 1068 ident: bib6 article-title: Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings publication-title: Retina – volume: 125 start-page: 708 year: 2018 end-page: 724 ident: bib4 article-title: Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management publication-title: Ophthalmology – ident: bib35 article-title: OPT-302 with ranibizumab in neovascular age-related macular degeneration (nAMD) (ShORe). ClinicalTrials.gov Identifier NCT04757610 – volume: 104 start-page: 103 year: 2011 end-page: 112 ident: bib23 article-title: Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells publication-title: J Neurooncol – volume: 15 start-page: 100 year: 1995 end-page: 110 ident: bib2 article-title: Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy publication-title: Retina – volume: 13 start-page: 8747 year: 2023 ident: bib14 article-title: Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan publication-title: Sci Rep – volume: 29 start-page: 19 year: 2010 end-page: 29 ident: bib3 article-title: Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? publication-title: Prog Retin Eye Res – volume: 93 start-page: 524 year: 2015 end-page: 532 ident: bib31 article-title: Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration publication-title: Acta Ophthalmol – volume: 17 start-page: 53 year: 2023 end-page: 70 ident: bib9 article-title: Polypoidal choroidal vasculopathy: an update on diagnosis and treatment publication-title: Clin Ophthalmol – volume: 2 start-page: 31 year: 2018 end-page: 37 ident: bib24 article-title: Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers publication-title: Ophthalmol Retina – volume: 53 start-page: 107 year: 2016 end-page: 139 ident: bib5 article-title: Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians publication-title: Prog Retin Eye Res – volume: 27 start-page: 589 year: 2007 end-page: 594 ident: bib7 article-title: Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy publication-title: Retina – volume: 65 start-page: 550 year: 2005 end-page: 563 ident: bib17 article-title: The biology of vascular endothelial growth factors publication-title: Cardiovasc Res – volume: 8 year: 2013 ident: bib22 article-title: The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer publication-title: PLoS One – volume: 38 start-page: 1509 year: 2018 end-page: 1517 ident: bib33 article-title: Choroidal vascular hyperpermeability as apredictor of treatment response for polypoidal choroidal vasculopathy publication-title: Retina – volume: 4 start-page: 250 year: 2020 end-page: 263 ident: bib28 article-title: Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration publication-title: Ophthalmol Retina – volume: 11 start-page: 161 year: 2017 end-page: 177 ident: bib34 article-title: Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis publication-title: Clin Ophthalmol – volume: 158 start-page: 309 year: 2014 end-page: 318.e2 ident: bib8 article-title: Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging publication-title: Am J Ophthalmol – volume: 346 start-page: 45 year: 2014 end-page: 52 ident: bib21 article-title: Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression publication-title: Cancer Lett – volume: 20 start-page: 15 year: 2020 ident: bib27 article-title: Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients publication-title: BMC Ophthalmol – volume: 403 start-page: 1141 year: 2024 end-page: 1152 ident: bib38 article-title: Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial publication-title: Lancet – volume: 128 start-page: 443 year: 2021 end-page: 452 ident: bib10 article-title: Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup publication-title: Ophthalmology – volume: 399 start-page: 729 year: 2022 end-page: 740 ident: bib37 article-title: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials publication-title: Lancet – volume: 146 start-page: 128 year: 2016 end-page: 136 ident: bib25 article-title: Response to anti-VEGF-A treatment of endothelial cells in vitro publication-title: Exp Eye Res – volume: 32 start-page: 1453 year: 2012 end-page: 1464 ident: bib11 article-title: EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy publication-title: Retina – volume: 94 start-page: 664 year: 2004 end-page: 670 ident: bib18 article-title: Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability publication-title: Circ Res – volume: 157 start-page: 1013 year: 2014 end-page: 1021 ident: bib32 article-title: Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration publication-title: Am J Ophthalmol – volume: 10 start-page: 1 year: 1990 end-page: 8 ident: bib1 article-title: Idiopathic polypoidal choroidal vasculopathy (IPCV) publication-title: Retina – volume: 130 start-page: 588 year: 2023 end-page: 597 ident: bib29 article-title: A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration publication-title: Ophthalmology – volume: 32 start-page: 1453 year: 2012 ident: 10.1016/j.xops.2025.100759_bib11 article-title: EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy publication-title: Retina doi: 10.1097/IAE.0b013e31824f91e8 – volume: 136 start-page: 786 year: 2018 ident: 10.1016/j.xops.2025.100759_bib13 article-title: Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2018.1804 – volume: 20 start-page: 15 year: 2020 ident: 10.1016/j.xops.2025.100759_bib27 article-title: Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients publication-title: BMC Ophthalmol doi: 10.1186/s12886-019-1278-8 – volume: 27 start-page: 589 year: 2007 ident: 10.1016/j.xops.2025.100759_bib7 article-title: Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy publication-title: Retina doi: 10.1097/01.iae.0000249386.63482.05 – volume: 8 year: 2013 ident: 10.1016/j.xops.2025.100759_bib22 article-title: The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer publication-title: PLoS One doi: 10.1371/journal.pone.0077117 – volume: 130 start-page: 588 year: 2023 ident: 10.1016/j.xops.2025.100759_bib29 article-title: A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration publication-title: Ophthalmology doi: 10.1016/j.ophtha.2023.02.001 – volume: 346 start-page: 45 year: 2014 ident: 10.1016/j.xops.2025.100759_bib21 article-title: Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.12.004 – volume: 2 start-page: 31 year: 2018 ident: 10.1016/j.xops.2025.100759_bib24 article-title: Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers publication-title: Ophthalmol Retina doi: 10.1016/j.oret.2017.04.004 – volume: 4 start-page: 250 year: 2020 ident: 10.1016/j.xops.2025.100759_bib28 article-title: Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration publication-title: Ophthalmol Retina doi: 10.1016/j.oret.2019.10.008 – volume: 53 start-page: 107 year: 2016 ident: 10.1016/j.xops.2025.100759_bib5 article-title: Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2016.04.002 – volume: 93 start-page: 524 year: 2015 ident: 10.1016/j.xops.2025.100759_bib31 article-title: Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration publication-title: Acta Ophthalmol doi: 10.1111/aos.12653 – volume: 128 start-page: 443 year: 2021 ident: 10.1016/j.xops.2025.100759_bib10 article-title: Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup publication-title: Ophthalmology doi: 10.1016/j.ophtha.2020.08.006 – volume: 11 start-page: 161 year: 2017 ident: 10.1016/j.xops.2025.100759_bib34 article-title: Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S125676 – volume: 158 start-page: 309 year: 2014 ident: 10.1016/j.xops.2025.100759_bib8 article-title: Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2014.05.004 – volume: 8 start-page: 464 year: 2007 ident: 10.1016/j.xops.2025.100759_bib19 article-title: Molecular regulation of angiogenesis and lymphangiogenesis publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm2183 – volume: 14 year: 2025 ident: 10.1016/j.xops.2025.100759_bib40 article-title: Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS) publication-title: Asia Pac J Ophthalmol (Phila) doi: 10.1016/j.apjo.2025.100144 – volume: 32 start-page: 1057 year: 2012 ident: 10.1016/j.xops.2025.100759_bib6 article-title: Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings publication-title: Retina doi: 10.1097/IAE.0b013e31823beb14 – volume: 13 start-page: 8747 year: 2023 ident: 10.1016/j.xops.2025.100759_bib14 article-title: Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan publication-title: Sci Rep doi: 10.1038/s41598-023-35759-4 – volume: 65 start-page: 550 year: 2005 ident: 10.1016/j.xops.2025.100759_bib17 article-title: The biology of vascular endothelial growth factors publication-title: Cardiovasc Res doi: 10.1016/j.cardiores.2004.12.002 – volume: 10 start-page: 1 year: 1990 ident: 10.1016/j.xops.2025.100759_bib1 article-title: Idiopathic polypoidal choroidal vasculopathy (IPCV) publication-title: Retina doi: 10.1097/00006982-199010010-00001 – volume: 94 start-page: 664 year: 2004 ident: 10.1016/j.xops.2025.100759_bib18 article-title: Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability publication-title: Circ Res doi: 10.1161/01.RES.0000118600.91698.BB – volume: 104 start-page: 103 year: 2011 ident: 10.1016/j.xops.2025.100759_bib23 article-title: Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells publication-title: J Neurooncol doi: 10.1007/s11060-010-0480-6 – volume: 29 start-page: 19 year: 2010 ident: 10.1016/j.xops.2025.100759_bib3 article-title: Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2009.10.001 – volume: 146 start-page: 128 year: 2016 ident: 10.1016/j.xops.2025.100759_bib25 article-title: Response to anti-VEGF-A treatment of endothelial cells in vitro publication-title: Exp Eye Res doi: 10.1016/j.exer.2015.12.014 – volume: 403 start-page: 1141 year: 2024 ident: 10.1016/j.xops.2025.100759_bib38 article-title: Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(24)00063-1 – volume: 53 start-page: 3663 year: 2012 ident: 10.1016/j.xops.2025.100759_bib30 article-title: Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.12-9619 – volume: 3 start-page: 31 year: 2017 ident: 10.1016/j.xops.2025.100759_bib26 article-title: Retinal and choroidal angiogenesis: a review of new targets publication-title: Int J Retina Vitreous doi: 10.1186/s40942-017-0084-9 – volume: 273 start-page: 6599 year: 1998 ident: 10.1016/j.xops.2025.100759_bib20 article-title: A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities publication-title: J Biol Chem doi: 10.1074/jbc.273.12.6599 – volume: 399 start-page: 729 year: 2022 ident: 10.1016/j.xops.2025.100759_bib37 article-title: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials publication-title: Lancet doi: 10.1016/S0140-6736(22)00010-1 – volume: 137 start-page: 661 year: 2019 ident: 10.1016/j.xops.2025.100759_bib39 article-title: Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2019.0565 – volume: 15 start-page: 100 year: 1995 ident: 10.1016/j.xops.2025.100759_bib2 article-title: Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy publication-title: Retina doi: 10.1097/00006982-199515020-00003 – volume: 125 start-page: 708 year: 2018 ident: 10.1016/j.xops.2025.100759_bib4 article-title: Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management publication-title: Ophthalmology doi: 10.1016/j.ophtha.2017.11.019 – volume: 38 start-page: 1509 year: 2018 ident: 10.1016/j.xops.2025.100759_bib33 article-title: Choroidal vascular hyperpermeability as apredictor of treatment response for polypoidal choroidal vasculopathy publication-title: Retina doi: 10.1097/IAE.0000000000001758 – volume: 157 start-page: 1013 year: 2014 ident: 10.1016/j.xops.2025.100759_bib32 article-title: Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2014.01.019 – volume: 17 start-page: 53 year: 2023 ident: 10.1016/j.xops.2025.100759_bib9 article-title: Polypoidal choroidal vasculopathy: an update on diagnosis and treatment publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S385827 – volume: 83 start-page: 1031 year: 2006 ident: 10.1016/j.xops.2025.100759_bib16 article-title: The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium publication-title: Exp Eye Res doi: 10.1016/j.exer.2006.05.007 – volume: 26 start-page: 426 year: 2012 ident: 10.1016/j.xops.2025.100759_bib12 article-title: Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy publication-title: Eye (Lond) doi: 10.1038/eye.2011.324 |
| SSID | ssj0002513241 |
| Score | 2.2997987 |
| Snippet | The aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the... PurposeThe aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the... The aim of this study was to assess the efficacy of sozinibercept, a novel "trap" inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for the... Purpose: The aim of this study was to assess the efficacy of sozinibercept, a novel “trap” inhibitor of VEGF-C and VEGF-D, when combined with ranibizumab for... |
| SourceID | doaj proquest pubmed crossref elsevier |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 100759 |
| SubjectTerms | Neovascular age-related macular degeneration Ophthalmology Polypoidal choroidal vasculopathy Sozinibercept VEGF-C/-D |
| Title | Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666914525000570 https://www.clinicalkey.es/playcontent/1-s2.0-S2666914525000570 https://dx.doi.org/10.1016/j.xops.2025.100759 https://www.ncbi.nlm.nih.gov/pubmed/40933661 https://www.proquest.com/docview/3249847297 https://doaj.org/article/2919c3e804c34e0ea2bccb91fbc1cdee |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s3yqIzEAYSiJn4ka25l6dIiFa0orXqzHHuiBkGy2odE-wP43cw4yWqRgF64RFHk2NbMeOazPQ_GXgopS1M6lbigRaIC6sFS5CEpnAweLWDwkmKHjz_lh6fq47k-3yr1RT5hXXrgjnB7wmTGSxinyksFKThRel-arCp95gMAad_UpFubKdLBaLURKWR9lEzn0PWjnVN-bqGjZwAlJ92yRDFh_28G6W-AMxqe6R12u0eMfL-b6V12A5p77OZxfyd-n_08aa_qhhw_yEOFv9pvVnVydvBhmkz2kvevOa543P1C4HTkyj87bFpfrb-7kiNe5bP22-W8rQOOMLloF93bWXRPbala8eVbPrtAS8ePjko-W0CAKnaGCicGhPAhq8kDdjo9-DI5TPrqConXQq8S2vg4X0GljcQH4o4CDHZSal2lPnfg8qBQVYrUj5UrIHMGCa2BUtJro7V8yHaatoHHjGcFCkKllROVU1QACypwyodxASBdWozYm4HSdt4l0bCDd9lXS3yxxBfb8WXE3hEzNi0pAXb8gGJhe7Gw14nFiMmBlXaIMUWtiB3V_xy6-NNfsOwX9tJmdilsak8Q1-Qmi5fCFM-bjpje_Nljlw6TXDvii0HOLC5suq1xDbTrpUX5NQgdhEHyPeoEcEMSRedQiKye_A9SPWW3aEKdD_IztrNarOE5Iq1VuRsX1W48AvsFMhMpsw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sozinibercept+%28Anti-VEGF-C%2F-D%29+Combined+with+Ranibizumab+for+Polypoidal+Choroidal+Vasculopathy%3A+Phase+IIb+Predefined+Subgroup+Analysis&rft.jtitle=Ophthalmology+science+%28Online%29&rft.au=Cheung%2C+Chui+Ming+Gemmy&rft.au=Jackson%2C+Timothy+L.&rft.au=Wykoff%2C+Charles+C.&rft.au=Khanani%2C+Arshad+M.&rft.date=2025-07-01&rft.issn=2666-9145&rft.eissn=2666-9145&rft.volume=5&rft.issue=4&rft.spage=100759&rft_id=info:doi/10.1016%2Fj.xops.2025.100759&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_xops_2025_100759 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26669145%2FS2666914525X00038%2Fcov150h.gif |